Therefore, BRAF and MEK inhibitor combinatorial treatments, in the form of trametinib + dabrafenib and cobimetinib + vemurafenib, were approved by the FDA for patients with advanced BRAFV600E melanoma [55,56]. The gene discussed is BRAF; the disease is melanoma.